Processing your request

please wait...

Case Page


Case Status:    ONGOING    
On or around 02/16/2021 (Date of last review)

Filing Date: February 16, 2021

According to the Complaint, Nantkwest, Inc. is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases.

On December 21, 2020, NantKwest and ImmunityBio, Inc. issued a joint press release announcing the Proposed Transaction, pursuant to which NantKwest will merge with ImmunityBio through NantKwest’s wholly owned subsidiary Nectarine Merger Sub, Inc.

On February 2, 2021, NantKwest filed a Schedule 14A Definitive Proxy Statement with the SEC. The Complaint alleges the Proxy Statement, which recommends that NantKwest stockholders vote in favor of the Proposed Transaction, omits or misrepresents material information concerning, among other things: (i) the Company’s and ImmunityBio’s financial projections and the data and inputs underlying the financial valuation analyses that support the fairness opinion provided by one of the special committee of the Board’s financial advisors; and (ii) the potential conflicts of interest faced by the Special Committee’s advisors.

Protected Content

Please Log In or Sign Up to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.